Drugs / E7130
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03444701 | Feb 2018 → Dec 2024 | cancer | Eisai Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-06-17 | Eisai Inc. | Results TOTAL SYNTHESIS AND NONCLINICAL STUDY RESULTS OF A NOVEL ANTICANCER DRUG CANDIDATE E7130 DERIVED FROM TOTAL SYNTHESIS OF HALICHONDRIN FOUND IN JOINT RESEARCH BETWEEN EISAI AND HARVARD UNIVERSITY SCIENTISTS, PUBLISHED IN SCIENTIFIC REPORTS eisai.com ↗
These results have been published in Scientific Reports , a scientific journal of Nature . |
All press releases naming this drug 1 release
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E7130 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03444701 ↗ |
| Known as | C52-halichondrin-b amine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802148 ↗ |
| Action | Inhibit | “First-in-human study of E7130 (a tumor microenvironment-ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose-escalation part.” PMID 37080942 ↗ Apr 2023 |
| Modality | Small molecule | — CHEMBL4802148 ↗ |
| Route | Intravenous | “E7130 was administered intravenously in two cycles: day 1 of a 21-day cycle (Q3W) or days 1 and 15 of a 28-day cycle (Q2W).” PMID 37080942 ↗ Apr 2023 |